Pharmacy

Pharmacy formulary and medical policy changes for January 2027

October 15, 2026

Read the full newsletter here.

Beginning January 2027, some drugs will experience a formulary drug list change. Read more about formulary drug list changes.

Also, starting in January 2027, the following drugs will require a new prior authorization:

Condition

Drugs requiring a new prior authorization

Preferred alternatives

Cancer

Kanjinti (trastuzumab-anns)

Ogivri (trastuzumab-dkst)
Trazimera (trastuzumab-qyyp)

Cancer and autoimmune conditions

Truxima (rituximab-abbs)

Riabni (rituximab-arrx)
Ruxience (rituximab-pvvr)

Diabetes

Farxiga (dapagliflozin)
Jardiance (empagliflozin)
Synjardy (empagliflozin-metformin)
Synjardy XR (empagliflozin-metformin extended-release)
Xigduo XR (dapagliflozin-metformin extended-release)

Dapagliflozin
Dapagliflozin-metformin extended-release

Diabetes

Januvia (sitagliptin)
Janumet (sitagliptin-metformin)
Janumet XR (sitagliptin-metformin extended-release)
Jentadueto (linagliptin-metformin)
Jentadueto XR (linagliptin-metformin extended-release)
Tradjenta (linagliptin)

Sitagliptin
Sitagliptin-metformin
Sitagliptin-metformin extended-release
Saxagliptin

How we’re notifying members

Impacted members will receive a letter in November 2026 notifying them of the change or the member’s provider was notified of the change in our October 2026 issue of Provider News.

If you have any questions about these formulary and prior authorization changes, please contact your Premera representative.